Cat NO.:	HS-EL0025Mo
Product:	Sunlong Medical™ Mouse IFN-γ High Sensitivity ELISA Kit
Storage	4℃ (unopened) for two years
Shipping Condition	4℃
Sample Type:	Serum | plasma | cell culture supernatant and other biological samples
Spike Recovery Range:	88% - 115%
Mean Spike Recovery:	104%
CV of Intra plate:	4.7 % - 4.8 %
CV of Inter plate:	1.2% - 5.0 %
NCBI_Gene:	15978
UniProtKB:	P01580

 

PLATFORM	ELISA
PLATE	Detachable 96-well plate
SIZE	96T/48T
STORAGE	If the reagent kit is unopened, it should be stored at 4℃. However, if it has been opened, the standard solution should be stored at -20℃, while the other components should be stored at 4℃.
DELIVERY	4℃ blue ice transportation
COMPONENTS	96-well polystyrene enzyme-linked immunosorbent assay (ELISA) plate coated with anti-IFN-γ monoclonal antibody Mouse IFN-γ freeze-dried standard IFN-γ detect Antibody Standard Diluent HRP-labeled streptavidin Signal enhancer concentrate Signal enhancer diluent Assay Buffer(10×) Substrate TMB Stop Solution Washing Buffer(20×) Sealing Film
ASSAY PRINCIPLE	This kit utilizes the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection technique.Specific anti-mouse IFN-γ antibodies are precoated on a high-affinity ELISA plate.Standards and test samples are added to the wells of the ELISA plate. After incubation, the IFN-γ present in the samples binds to the solid-phase antibodies. After washing to remove unbound substances, biotinylated detection antibodies are added and incubated. After washing to remove unbound biotinylated antibodies, streptavidin-HRP labeled with horseradish peroxidase is added. After washing again, a signal enhancer is added and incubated. After washing to remove unbound substances, Streptavidin-HRP is added once more. After washing, a colorimetric substrate, TMB, is added and the plate is incubated in the dark for color development. The intensity of the color reaction is directly proportional to the concentration of IFN-γ in the samples. A stop solution is added to terminate the reaction, and the absorbance value is measured at a wavelength of 450 nm (with a reference wavelength range of 570-630 nm).

 

1.Blocking BAFF Alleviates Hepatic Fibrosis in Schistosoma japonicum-Infected Mice

2.The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation

3.Lipid Mediators Metabolic Chaos of Asthmatic Mice Reversed by Rosmarinic Acid

4.Synergistic Antitumor Effect of Grifola frondose Polysaccharide—Protein Complex in Combination with Cyclophosphamide in H22 Tumor-Bearing Mice

5.Heat-Killed Bifidobacterium longum BBMN68 in Pasteurized Yogurt Alleviates Mugwort Pollen-Induced Allergic Airway Responses through Gut Microbiota Modulation in a Murine Model

6.Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by regulating HMGB1 release and autophagic degradation of TGF-β1

7.The influence of Hyssopus cuspidatus Boriss extract on lipid mediators metabolism network in asthmatic mice

8.Toxoplasma gondii gra5 deletion mutant protects hosts against Toxoplasma gondii infection and breast tumors

9.Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice

10.Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma

11.Dissolving Microneedle Arrays as a Hepatitis B Vaccine Delivery System Adjuvanted by APC-Targeted Poly (Lactic-co-Glycolic Acid) (PLGA) Nanoparticles

12.Gut microbiota mediated the effects of high relative humidity on lupus in female MRL/lpr mice

13.Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain

14.TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer

15.Synergetic regulation of cancer cells and exhausted T cells to fight cold tumors with a fluorinated EGCG-based nanocomplex

16.Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA

 

Cartpieces

• 
• 1

  1Delete

• 
• 6

  6Delete

• 
• H

  HDelete

• 
• S

  SDelete

• 
• +

  +Delete

• 
• 1

  1Delete

• 
• 2

  2Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 6

  6Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• S

  SDelete

• 
• I

  IDelete

• 
• <

  <Delete

• 
• i

  iDelete

• 
• i

  iDelete

• Delete

• 
• 1

  1Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• Delete

• 
• 2

  2Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• Delete

• 
• -

  -Delete

• 
• -

  -Delete

• 
• 0

  0Delete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• f

  fDelete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• Delete

• 
• <

  <Delete

• Delete

• 
• S

  SDelete

• Delete

• Delete

• 
• 6

  6Delete

• 
• $

  $Delete

• Delete

• 
• 0

  0Delete

• Delete

• Delete

• Delete

• 
• b

  bDelete

• 
• S

  SDelete

• 
• 5

  5Delete

• 
• S

  SDelete

Totalgoods,subtotals:￥Checkout